Company Overview and News

FirstService Declares Quarterly Cash Dividend on Common Shares

2018-05-15 globenewswire
TORONTO, May 15, 2018 (GLOBE NEWSWIRE) -- FirstService Corporation (TSX:FSV) (NASDAQ:FSV) ("FirstService") announced today that its Board of Directors has declared a quarterly cash dividend on the outstanding Subordinate Voting Shares and Multiple Voting Shares of the Company (together, the "Common Shares") of US$0.135 per Common Share. The dividend is payable on July 6, 2018 to holders of Common Shares of record at the close of business on June 29, 2018.

FirstService Corp's (FSV) CEO Scott Patterson on Q1 2018 Results - Earnings Call Transcript

2018-04-25 seekingalpha
Welcome to the first quarter investors conference call. Today's call is being recorded. Legal counsel requires us to advise that the discussion scheduled to take place today may contain forward-looking statements that involve known and unknown risks and uncertainties. Actual results may be materially different from any future results, performance or achievements contemplated in the forward-looking statements.

FirstService Reports Strong First Quarter Results

2018-04-25 globenewswire
TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- FirstService Corporation (TSX:FSV) (NASDAQ:FSV) today reported strong results for its first quarter ended March 31, 2018. All amounts are in US dollars.

FirstService Brands Completes Four Acquisitions

2018-04-19 globenewswire
TORONTO, April 19, 2018 (GLOBE NEWSWIRE) -- FirstService Corporation (TSX:FSV) (NASDAQ:FSV) (“FirstService”) today announced that it has expanded its FirstService Brands company-owned operations with four recent acquisitions within its California Closets and Paul Davis Restoration (“PDR”) service platforms. Terms of the transactions were not disclosed.

FirstService Corporation Announces Upcoming Meeting and Financial Reporting Dates

2018-04-03 globenewswire
TORONTO, April 03, 2018 (GLOBE NEWSWIRE) -- FirstService Corporation (TSX:FSV) (NASDAQ:FSV) announced today that it will host its Annual and Special Meeting of Shareholders on Wednesday, April 11, 2018 in Toronto, Ontario at The Design Exchange, 234 Bay Street, Toronto-Dominion Centre. D. Scott Patterson, President & Chief Executive Officer, and Jeremy Rakusin, Chief Financial Officer, are scheduled to present at the meeting.

Kennedy Wilson Cheers Investors With Share Buyback Program

2018-03-23 zacks
Kennedy Wilson (KW - Free Report) has announced a $250-million share repurchase program as part of its effort to return value to shareholders. The company intends to fund this move with the proceeds from disposition of non-core assets in future. Particularly, this global real estate investment company plans to complete the repurchase program within one and a half year and make the share buybacks in the open market, privately negotiated deals, through the net settlement of its restricted stock grants or otherwise.

Why Should You Add CBRE Group (CBG) Stock to Your Portfolio?

2018-03-14 zacks
CBRE Group, Inc. (CBG - Free Report) has secured the top spot in the global rankings for commercial real estate investment sales for 2017. The data is per Real Capital Analytics (RCA). This, in fact, is the seventh consecutive year of the company achieving the first position. In fact, per the RCA data, CBRE had 22.3% market share in 2017 across all property types on a global basis, which is a massive 650 basis points ahead of its closest competitor.

CBRE Retains Commercial Property Investment Sales Top Spot

2018-03-13 zacks
Delighting its shareholders, CBRE Group, Inc. (CBG - Free Report) announced that it has once again secured the top spot in the global rankings for commercial real estate investment sales for 2017. The data is as per Real Capital Analytics (RCA). This, in fact, is the seventh consecutive year of the company achieving the first position. RCA tracks global commercial real estate sales of $10 million and higher.

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSX:FSV / Firstservice Corporation on message board site Silicon Investor.

Freshstart Venture Capital (FSVC)